Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal宣佈Onct-534治療復發/難治轉移性去勢抵抗性前列腺癌的1/2期研究的第五劑量隊列的註冊工作已完成並開始給藥